Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Self-Compassion and Quality of Life in Nursing Students With Premenstrual Syndrome

20. juli 2026 oppdatert av: Güzin Ünlü Suvari, Acibadem University

The Mediating Role of Self-Compassion in the Association Between Premenstrual Symptom Severity and Premenstrual Syndrome-Specific Quality of Life Among Nursing Students With Premenstrual Syndrome

Premenstrual syndrome (PMS) is one of the most common menstrual disorders among women of reproductive age and is characterized by recurrent physical, emotional, cognitive, and behavioral symptoms during the late luteal phase of the menstrual cycle. These symptoms may adversely affect academic performance, daily functioning, interpersonal relationships, and quality of life. Although previous studies have demonstrated that greater premenstrual symptom severity is associated with poorer quality of life, the psychological mechanisms underlying this relationship remain unclear. Self-compassion, defined as a compassionate and nonjudgmental attitude toward oneself during times of difficulty, has been identified as a protective psychological factor associated with better emotional well-being and adaptive coping. However, its mediating role in the relationship between premenstrual symptom severity and premenstrual syndrome-specific quality of life has not been adequately investigated. This cross-sectional study aims to examine the association between premenstrual symptom severity and premenstrual syndrome-specific quality of life and to investigate the mediating role of self-compassion among nursing students who meet the study criteria for PMS (Premenstrual Syndrome Scale score ≥110).

Studieoversikt

Studietype

Observasjonsmessig

Registrering (Faktiske)

164

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Ataşehir
      • Istanbul, Ataşehir, Tyrkia (Türkiye)
        • Acibadem University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Female undergraduate nursing students aged 18-25 years with premenstrual syndrome, defined as a Premenstrual Syndrome Scale (PMSS) score of 110 or higher, who meet the study eligibility criteria.

Beskrivelse

Inclusion Criteria:

  • Female nursing students aged 18 to 25 years.
  • Regular menstrual cycles.
  • Premenstrual Syndrome Scale (PMSS) total score of 110 or higher, indicating premenstrual syndrome according to the established cut-off value.
  • Willingness to participate and provide written informed consent.

Exclusion Criteria:

  • Receiving ongoing physician-prescribed pharmacological treatment for premenstrual syndrome (e.g., oral contraceptives, hormonal therapy, or selective serotonin reuptake inhibitors).
  • Irregular menstrual cycles.
  • History of chronic medical disease.
  • History of psychiatric disorders.
  • Incomplete study questionnaires.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Nursing Students Meeting the Study Criteria for PMS
Female nursing students aged 18-25 years with Premenstrual Syndrome Scale (PMSS) scores ≥110 who meet the study eligibility criteria.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sociodemographic, Menstrual, and Lifestyle Characteristics
Tidsramme: Baseline
Sociodemographic, menstrual, reproductive, and lifestyle characteristics will be collected using a researcher-developed questionnaire consisting of 20 items. The questionnaire includes information on age, academic year, menstrual history, menstrual pain characteristics, premenstrual syndrome history, analgesic use, sleep characteristics, caffeine consumption, fast-food consumption, sugar intake, and other lifestyle-related factors.
Baseline
Premenstrual Syndrome Scale (PMSS)
Tidsramme: Baseline
Premenstrual symptom severity will be assessed using the Premenstrual Syndrome Scale (PMSS). The PMSS is a 44-item self-report instrument consisting of nine subscales (depressive affect, anxiety, fatigue, irritability, depressive thoughts, pain, appetite changes, sleep changes, and bloating). Total scores range from 44 to 220, with higher scores indicating greater premenstrual symptom severity. In accordance with the original scale, a total PMSS score of 110 or higher, representing the established cut-off for premenstrual syndrome, will be used as an eligibility criterion for study enrollment.
Baseline
Premenstrual Syndrome-Specific Quality of Life Scale (PMS-QoL)
Tidsramme: Within approximately 1 week after baseline
Premenstrual syndrome-specific quality of life will be assessed using the Premenstrual Syndrome-Specific Quality of Life Scale (PMS-QoL). The PMS-QoL is a 22-item self-report instrument consisting of three domains: physical well-being, emotional well-being, and social well-being. Higher scores indicate better premenstrual syndrome-specific quality of life.
Within approximately 1 week after baseline
Self-Compassion Scale (SCS)
Tidsramme: Within approximately 1 week after baseline
Self-compassion will be assessed using the Self-Compassion Scale (SCS). The SCS is a 26-item self-report instrument comprising six dimensions: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Higher scores indicate greater self-compassion.
Within approximately 1 week after baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. juni 2026

Primær fullføring (Faktiske)

15. juli 2026

Studiet fullført (Faktiske)

15. juli 2026

Datoer for studieregistrering

Først innsendt

29. juni 2026

Først innsendt som oppfylte QC-kriteriene

29. juni 2026

Først lagt ut (Faktiske)

6. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

De-identified individual participant data will be available upon reasonable request to the corresponding investigator.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere